<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clofarabine (2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) is a second-generation <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analog with activity in <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As clofarabine is a potent inhibitor of <z:chebi fb="0" ids="26561">ribonucleotide</z:chebi> reductase (RnR), we hypothesized that clofarabine will modulate ara-c <z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi> accumulation and increase the antileukemic activity of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C) </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a phase 1-2 study of clofarabine plus ara-C in 32 patients with relapsed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (25 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>], 2 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> [ALL]), 4 high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and 1 blast-phase <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>).(1) Clofarabine was given as a 1-hour intravenous infusion for 5 days (days 2 through 6) followed 4 hours later by ara-C at 1 g/m(2) per day as a 2-hour intravenous infusion for 5 days (days 1 through 5) </plain></SENT>
<SENT sid="3" pm="."><plain>The phase 2 dose of clofarabine was 40 mg/m(2) per day for 5 days </plain></SENT>
<SENT sid="4" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> patients, 7 (22%) achieved complete remission (CR), and 5 (16%) achieved CR with incomplete platelet recovery (CRp), for an overall response rate of 38% </plain></SENT>
<SENT sid="5" pm="."><plain>No responses occurred in 3 patients with ALL and <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>One patient (3%) died during induction </plain></SENT>
<SENT sid="7" pm="."><plain>Adverse events were mainly less than or equal to grade 2, including transient liver test abnormalities, <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, skin <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rashes</z:e>, mucositis, and palmoplantar erythrodysesthesias </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma clofarabine levels generated clofarabine <z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi> accumulation, which resulted in an increase in ara-<z:chebi fb="22" ids="17677">CTP</z:chebi> in the leukemic blasts </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of clofarabine with ara-C is safe and active </plain></SENT>
<SENT sid="10" pm="."><plain>Cellular pharmacology data support the biochemical modulation strategy </plain></SENT>
</text></document>